- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07559513
A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP) (OPTIMA-2)
Phase 3 Evaluation of the Safety, Pharmacokinetics, and Efficacy of Garetosmab (Anti-Activin A Monoclonal Antibody) in Children and Adolescents With Fibrodysplasia Ossificans Progressiva
This study is researching an experimental drug called garetosmab, referred to as "study drug". The study is focused on children and adolescent participants with FOP. For United States: Ages 4 to less than 18 years; for non-US sites only: Ages 2 to less than 18 years.
The aim of the study is to see how safe, tolerable, and effective the study drug is.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Clinical Trials Administrator
- Telefonnummer: 844-734-6643
- E-post: clinicaltrials@regeneron.com
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
-
For USA participants, age criteria are 4 to < 18 years old, at the time of the administration of the first dose of study intervention. Non-USA participants age criteria are 2 to < 18 years old
-
Must have a confirmation of FOP diagnosis, as described in the protocol
-
At the time of enrollment, participants must weight:
- Cohort 1: more than 30 kg (or 66.1 pounds)
- Cohort 2: more than 30 kg (or 66.1 pounds)
- Cohort 3: less than or equal to 30 kg (or 66.1 pounds)
Key Exclusion Criteria:
- Cumulative Analog Joint Involvement Scale (CAJIS) score > 19 at the time of screening
- Participant has significant concomitant illness or history of significant illness, as described in the protocol
- Previous history or diagnosis of cancer
- Ongoing significant viral or bacterial illness, within 2 weeks of the first study drug administration
- History of severe respiratory compromise requiring oxygen, respiratory support
- Known history of cerebral vascular malformation
- Participants with a history of severe, non-traumatic bleeding requiring transfusion or hospitalization for hemodynamic compromise
- Participants with a known pre-existing medical history of a bleeding diathesis, as described in the protocol
- Participants who have used palovarotene in the last 30 days or within 5 half-lives of the therapy, whichever is longer from the day of randomization
NOTE: Other Protocol-defined Inclusion/Exclusion Criteria Apply
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Cohort 1: Adolescents
Participants aged 12 - 18 years old |
Administered per the protocol
Andre navn:
|
|
Eksperimentell: Cohort 2: Children
Children who are 4 to 12 years old (for non-US sites only 2 to 12 years old) |
Administered per the protocol
Andre navn:
|
|
Eksperimentell: Cohort 3: Children and Adolescents
Participants and Children aged 4 to 18 years old (for non-US sites only 2 to 18 years old) |
Administered per the protocol
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Severity of TEAEs
Tidsramme: Baseline to week 56
|
Baseline to week 56
|
|
Concentrations of functional garetosmab in serum
Tidsramme: Through week 56
|
Through week 56
|
|
Occurrence of Treatment-Emergent Adverse Event (TEAEs)
Tidsramme: Baseline to week 56
|
Baseline to week 56
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of new HO lesions
Tidsramme: At week 28 and week 56
|
At week 28 and week 56
|
|
|
Occurrence of new HO lesions
Tidsramme: At week 28 and week 56
|
At week 28 and week 56
|
|
|
Number of clinician-assessed flare-ups
Tidsramme: Through week 28 and week 56
|
Through week 28 and week 56
|
|
|
Occurrence of clinician-assessed flare-ups
Tidsramme: Through week 28 and week 56
|
Through week 28 and week 56
|
|
|
Characteristics of menstrual cycles for female participants who reached menarche
Tidsramme: Over 28 weeks and 56 weeks
|
Over 28 weeks and 56 weeks
|
|
|
Concentrations of total activin A in serum
Tidsramme: Through week 56
|
Through week 56
|
|
|
Occurence of Anti-Drug Antibody (ADA) to garetosmab
Tidsramme: Through week 56
|
Through week 56
|
|
|
Magnitude of ADA to garetosmab
Tidsramme: Through week 56
|
Through week 56
|
|
|
Change from baseline in hearing function as assessed by audiometry
Tidsramme: At week 28 and week 56
|
At week 28 and week 56
|
|
|
Total volume of new Heterotopic Ossification (HO) lesions
Tidsramme: At week 28 and week 56
|
At week 28 and week 56
|
|
|
Change from baseline in total volume of HO lesions
Tidsramme: At week 28 and week 56
|
At week 28 and week 56
|
|
|
Change from baseline in Tanner puberty scale
Tidsramme: At week 28 and week 56
|
Tanner puberty scale or stages: Staging of sexual development is graded on a 5-point ordinal scale ranging from 1 (prepubertal) to 5 (adultlike) for female breast development, male external genitals, and pubic hair |
At week 28 and week 56
|
|
Height-for-age Z-Scores according to the World Health Organization (WHO) Growth Reference Data for Children
Tidsramme: Through week 56
|
Participants 5-19 years of age Z-score represents standardized measure of how far an individual deviated from study cohort average at baseline. A higher Z-score reflects better performance. |
Through week 56
|
|
Change from baseline in knee height
Tidsramme: At week 28 and week 56
|
At week 28 and week 56
|
|
|
Change from baseline in Pediatric Quality of Life inventory (PedsQL) scores
Tidsramme: At week 28 and week 56
|
Age-appropriate PedsQL Generic Core Scales will be used to measure HRQoL in children and adolescents. Response options include 5-point Likert scale (or 3-point Likert scale for the young children self-report) for each item asking about experience within the past week. Global scores are transformed to a 0 to 100 scale with higher scores indicating better quality of life. |
At week 28 and week 56
|
|
Acceptability or tolerability assessment via exit interview
Tidsramme: Up to week 52
|
Each interview will be conducted by trained external interviewers following a semi-structured interview guide of questions for the participants about their overall experience in the trial. |
Up to week 52
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Clinical Trial Management, Regeneron Pharmaceuticals
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Muskel- og skjelettsykdommer
- Muskelsykdommer
- Patologiske prosesser
- Metabolisme, medfødte feil
- Genetiske sykdommer, medfødte
- Metabolske sykdommer
- Bindevevssykdommer
- Karbohydratmetabolisme, medfødte feil
- Lysosomale lagringssykdommer
- Mucinoser
- Myositt
- Mukopolysakkaridoser
- Medfødte, arvelige og neonatale sykdommer og abnormiteter
- Patologiske tilstander, tegn og symptomer
- Ernæringsmessige og metabolske sykdommer
- Hud- og bindevevssykdommer
- Myositis Ossificans
- Mukopolysakkaridose IV
- Ossifikasjon, Heterotopic
Andre studie-ID-numre
- R2477-FOP-2413
- 2024-518415-19-01 (Ctis)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
IPD-delingstidsramme
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
Tilgangskriterier for IPD-deling
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
- ANALYTIC_CODE
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .